We believe that treatment decisions should be made between you and your health care teams, so please do not stop taking KESIMPTA without talking to your neurologist or medical professional about any questions you may have.

More information about COVID-19 can be found from the Centers for Disease Control and Prevention (CDC) or the World Health Organization (WHO).

Additional patient resources are available through these patient advocacy groups:

Multiple Sclerosis Association of America
National Multiple Sclerosis Society

Don't make any changes to your medication routine that aren't directed by your doctor. Otherwise, follow the general safety and hygiene guidelines from the experts at the Centers for Disease Control and Prevention, which include handwashing, social distancing, wearing a mask, and cleaning surfaces.

It's completely understandable to have questions about getting a COVID-19 vaccine if you're about to start taking KESIMPTA. Vaccines like the COVID-19 vaccines are an important part of public health.

As of December 2021, the available COVID-19 vaccines are inactivated, or "non-live," vaccines. Whenever possible, you should wait at least 2 weeks after getting an inactivated or "non-live" vaccine to begin taking KESIMPTA.

The KESIMPTA Prescribing Information does not advise against administering inactivated vaccines while on treatment; however, KESIMPTA may interfere with the effectiveness of inactivated vaccines. Your doctor may want to consider an assessment of your immune response after taking the vaccine to confirm it was effective.

You should talk to your doctor to better understand the types of vaccines available to you and how they may affect when you can begin your new treatment.

For more information about COVID-19 vaccines, visit the Centers for Disease Control and Prevention (CDC) website at CDC.gov, and search: COVID-19 vaccines.

It's completely understandable to have questions about getting a COVID-19 vaccine. Vaccines like the COVID-19 vaccines are an important part of public health.

As of December 2021, the available COVID-19 vaccines are inactivated, or "non-live," vaccines. The KESIMPTA Prescribing Information does not advise against administering inactivated vaccines while on treatment; however, KESIMPTA may interfere with the effectiveness of inactivated vaccines. Your doctor may want to consider an assessment of your immune response after taking the vaccine to confirm it was effective.

You should talk to your doctor to better understand the types of vaccines available to you and how to manage getting a vaccine while taking KESIMPTA.

We believe that treatment decisions should be made between you and your health care teams, so please do not stop taking KESIMPTA without first talking to your doctor about any questions you may have.

For more information about COVID-19 vaccines, visit the Centers for Disease Control and Prevention (CDC) website at CDC.gov and search: COVID-19 vaccines.

Adverse interactions between COVID-19 vaccines and KESIMPTA are not known.

Vaccines like the COVID-19 vaccines are an important part of public health. So, you should talk to your doctor to better understand the types of vaccines available to you and how to manage getting a vaccine while taking KESIMPTA.

We believe that treatment decisions should be made between you and your health care teams, so please do not stop taking KESIMPTA without first talking to your doctor about any questions you may have.

For more information about COVID-19 vaccines, visit the Centers for Disease Control and Prevention (CDC) website at CDC.gov and search: COVID-19 vaccines.

At this time, we do not anticipate any disruption in product supply. We are confident that our existing stock is sufficient to cover production and distribution needs.

If you have concerns about your medication and COVID-19, please reach out to your health care team for further assistance.

While Novartis does not anticipate any supply shortages, the Centers for Disease Control and Prevention (CDC) advises people to get an extra supply of all essential medications. Reach out to your health care team or pharmacy to arrange this.

For more information about CDC recommendations for staying safe during this outbreak, visit cdc.gov/coronavirus/2019-ncov.

We understand these are trying times, and Novartis is committed to making your medication accessible and affordable. If your insurance plan is changing, or you are wondering about your copay, you can call Alongside™ KESIMPTA at 1-855-KESIMPTA (1-855-537-4678), 8:30 AM–8:00 PM ET, Mon–Fri. We can help you figure out your options to help make KESIMPTA more affordable.

You could pay as little as $0 for your monthly KESIMPTA prescriptions through the copay program* if you have commercial or private prescription insurance. Click here or call 1-855-KESIMPTA (1-855-537-4678), 8:30 AM–8:00 PM ET, Mon–Fri.

Get up to 12 months of KESIMPTA for free.^† If you have commercial or private insurance and your prescription coverage isn't initially approved, you may get up to 12 months of KESIMPTA for free through Alongside KESIMPTA while we work with your health care provider to try to secure coverage.

Visit the Novartis Patient Assistance Foundation, Inc. (NPAF), if you have limited or no prescription coverage or cannot afford your medication due to employment loss. You may be eligible to receive Novartis medications for free. Learn more at the Novartis Patient Assistance Foundation.

*Limitations apply. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. Patients with commercial insurance coverage for KESIMPTA may receive up to $18,000 in annual copay benefits. Patients with commercial insurance and an initial denial of coverage may receive up to 12 months of free product while coverage is pursued. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions at start.kesimpta.com.
^†Bridge Program: Must have commercial insurance, a valid prescription for KESIMPTA, and a denial of insurance coverage based on a prior authorization requirement to qualify. Eligible patients may receive a monthly maintenance dose for up to 12 months or until insurance coverage approval, whichever occurs first. Not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, VA, DoD or any other federal or state program, or where prohibited by law. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Other limitations may apply. Novartis reserves the right to rescind, revoke or amend this Program without notice.